These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31146663)

  • 1. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
    Hussein HA; Allam AS; Moaty ASA
    Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
    Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
    Arab J Gastroenterol; 2024 May; 25(2):118-124. PubMed ID: 38378359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
    Yakoot M; Abdo AM; Abdel-Rehim S; Helmy S
    EBioMedicine; 2017 Jul; 21():182-187. PubMed ID: 28647541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
    Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
    J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
    Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
    Abdel Moneim A; Suleiman HA; Mahmoud B; Mabrouk D; Zaky MY; Mahmoud B
    Clin Exp Med; 2020 May; 20(2):231-240. PubMed ID: 32076917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Nagaty A; Helmy SH; Abd El-Wahab EW
    Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir (+) daclatasvir (+) ribavirin in Egyptian patients with hepatitis C virus: Therapeutic outcomes and the prognostic role of natural killer cells.
    Zaid AB; Almady SK; Awad SM; Elabd MG; Saied SA; Saied AA; Elmalawany AM
    Curr Res Transl Med; 2024 Sep; 72(3):103443. PubMed ID: 38447269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
    Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
    Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents.
    Ciancio A; Bosio R; Bo S; Pellegrini M; Sacco M; Vogliotti E; Fassio G; Bianco Mauthe Degerfeld AGF; Gallo M; Giordanino C; Terzi di Bergamo L; Ribaldone D; Bugianesi E; Smedile A; Rizzetto M; Saracco GM
    J Med Virol; 2018 Feb; 90(2):320-327. PubMed ID: 28960353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
    Abdel Alem S; Elsharkawy A; Fouad R; Adel E; Abdellatif Z; Musa S; Nagy A; Hussein MS; Yosry A; Esmat G
    J Med Virol; 2017 Dec; 89(12):2181-2187. PubMed ID: 28688190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study).
    Boraie MB; Elnaggar YA; Ahmed MO; Mahmoud AM
    Diabetes Metab Syndr; 2019; 13(4):2641-2646. PubMed ID: 31405688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
    Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.